BARCLAYS PLC - INOZYME PHARMA INC ownership

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of INOZYME PHARMA INC
ValueSharesWeighting
Q3 2023$39
-30.4%
9,220
-9.7%
0.00%
Q2 2023$56
+55.6%
10,205
+62.7%
0.00%
Q1 2023$36
+414.3%
6,2730.0%0.00%
Q4 2022$7
-100.0%
6,273
-2.0%
0.00%
Q3 2022$17,000
-45.2%
6,4030.0%0.00%
Q2 2022$31,000
-13.9%
6,403
-26.7%
0.00%
Q1 2022$36,0008,7400.00%
Other shareholders
INOZYME PHARMA INC shareholders Q4 2023
NameSharesValueWeighting ↓
Pivotal bioVenture Partners Investment Advisor LLC 1,591,154$27,113,00010.69%
Burrage Capital Management LLC 242,517$4,132,0004.14%
CHI Advisors LLC 927,264$15,801,0003.68%
Sofinnova Investments, Inc. 2,028,308$34,562,0001.99%
Novo Holdings A/S 1,867,706$31,826,0001.41%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,178,985$37,130,0000.66%
RA Capital Management 2,003,653$34,142,0000.55%
NEA Management Company, LLC 2,444,379$41,652,0000.54%
Rock Springs Capital Management LP 840,272$14,318,0000.28%
SUVRETTA CAPITAL MANAGEMENT, LLC 365,172$6,223,0000.09%
View complete list of INOZYME PHARMA INC shareholders